The European medical cannabis industry is continuing to mature, seeing companies focused on science-based research push the boundaries of our
Earlier this week, Jazz dismissed a patent claim against Apotex, Canada’s largest generic drug producer, as it reached a settlement with the company, the details of which were undisclosed.
A groundbreaking achievement is flying under the radar. Epidiolex, the first FDA approved cannabis-derived drug developed by GW Pharmaceuticals, is on track to surpass $1 billion in annual revenue—a feat that puts it in the league of blockbuster drugs like Humira and Lipitor.
Jazz Pharmaceuticals [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”JAZZ” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Epidiolex (Epidyolex in the EU
In the intricate landscape of medical cannabis, Belgium has established a regulated framework to govern the use of cannabis for
Jazz Pharmaceuticals Jazz Pharmaceuticals, which has become the world’s largest exporter of medical cannabis products since it bought GW Pharmaceuticals
IT has been a difficult year for cannabis investors, and as the dreaded bear continues to hit global markets, many
Jonathan Havens of Saul Ewing Arnstein & Lehr LLP to talk about what the US FDA’s approval of GW Pharma’s
We won’t spam you
